Novartis Targets 5% Annual Sales Growth Through 2031

Novartis expects 5% constant-currency annual sales growth through 2031 and lifted peak-sales guidance for three drugs to a combined $18 billion.

InsiderFinance EditorialNVS options flow
November 19, 2026·2 min read
View all news articles
A pharmaceutical capsule rising on plain base, rendered as a single filled flat-vector object with clean edges and open.

KEY TAKEAWAYS

  • Novartis expects 5% constant-currency annual sales growth from 2026 through 2031.
  • Peak-sales guidance for Kesimpta, Scemblix and Leqvio rose to a combined $18 billion.
  • Novartis cited 35 or more potentially submission-enabling readouts through 2031.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Novartis (NVS) said on Nov. 19, 2026, that it expects net sales to grow at a 5% constant-currency compound annual rate from 2026 through 2031, and raised peak-sales guidance for Kesimpta, Scemblix and Leqvio to a combined $18 billion.

Three Drugs Lift Peak Sales Guidance

Novartis raised peak-sales guidance for Kesimpta to $6 billion to $8 billion, for Scemblix to $4 billion to $5 billion and for Leqvio to $4 billion to $5 billion. The three revised forecasts were previously a combined $14 billion.

The move followed a recent increase in peak-sales guidance for Rhapsido, also known as remibrutinib, to $8 billion across chronic spontaneous urticaria, chronic inducible urticaria and relapsing multiple sclerosis. Novartis said nine in-market assets now have peak-sales potential of $3 billion to $10 billion each, including Kisqali, Rhapsido, Cosentyx, Kesimpta, Pluvicto, Scemblix, Leqvio, the Zolgensma Group and Fabhalta. The company has pointed to existing brands as a source of growth alongside upcoming launches.

Pipeline Readouts Support Longer-Term Growth

Novartis identified 35 or more potentially submission-enabling readouts through 2031 and more than 30 potential high-value pipeline assets across four core therapeutic areas and three technology platforms. Ten late-stage assets were described as having multi-billion-dollar peak-sales guidance.

Management said, "Our full Phase I and II pipeline gives us further confidence that we can sustain mid-single-digit growth over the longer term." The company is also scaling artificial intelligence across research, development, manufacturing and commercial operations, though it did not quantify efficiency gains.

Novartis named pricing pressure, patent loss, clinical outcomes, technology adoption and reimbursement among material risks to its outlook. It also said core operating-income margin is on track to return to more than 40% by 2029.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

Amazon Says NYC Bill Could Add Up to $5 Per Order

Amazon Says NYC Bill Could Add Up to $5 Per Order

Amazon says a proposed New York City delivery-worker bill, Intro 518, could add up to $5 per order and push operations out of the city.

AMD Faces Short-Seller Claims Over Firmware in China

AMD Faces Short-Seller Claims Over Firmware in China

Hunterbrook Media alleges Advanced Micro Devices firmware kept showing up in IEIT Systems server products, which the U.S. blacklisted in March 2025.

Walmart Raises Outlook as Adjusted EPS Hits $0.65

Walmart Raises Outlook as Adjusted EPS Hits $0.65

Walmart raised fiscal 2027 guidance after third-quarter revenue rose 5.2% year over year to $188.8 billion and adjusted EPS hit $0.65.

AST SpaceMobile Upgraded to Buy by B. Riley, $48 Target

AST SpaceMobile Upgraded to Buy by B. Riley, $48 Target

B. Riley upgraded AST SpaceMobile to Buy from Neutral on Nov. 19, 2026, keeping a $48 price target and arguing the selloff reflected rocket risks.

Musk Says Tesla, SpaceX Would Probably Be Better Together

Musk Says Tesla, SpaceX Would Probably Be Better Together

Elon Musk said at the DealBook Summit that Tesla and SpaceX would probably be better together, though no transaction has been announced.

Anthropic Prices IPO at $83 a Share, Raising $81.3 Billion

Anthropic Prices IPO at $83 a Share, Raising $81.3 Billion

Anthropic priced its IPO at $83 a share, selling 980 million shares for about $81.3 billion in the largest stock-market debut on record.